MedTrace Logo

Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

NCT06504615 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 208

Last updated 2026-04-03

No results posted yet for this study

Summary

A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroesophageal junction cancer.

Conditions

  • Gastric Adenocarcinoma
  • Gastro-esophageal Junction Adenocarcinoma
  • Esophageal Adenocarcinoma (EAC)
  • Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG

nivolumab + chemotherapy

As prescribed by the treating clinician, as per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2028-08-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06504615 on ClinicalTrials.gov